1) Cutsem, E. V. et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAFV600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol 37, JCO.18.02459-11 (2019).
2) Tabernero, J. et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 39, 273–284 (2021).